Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 249Rectal Neoplasms 154Pancreatic Neoplasms 125Stomach Neoplasms 105Colonic Neoplasms 104Esophageal Neoplasms 90Neoplasm Metastasis 69Breast Neoplasms 61Squamous Cell Carcinoma of Head and Neck 47Carcinoma, Hepatocellular 42Adenocarcinoma Of Esophagus 41Head and Neck Neoplasms 39Esophageal Squamous Cell Carcinoma 38Neoplasms 37Nasopharyngeal Carcinoma 30Adenocarcinoma 24Cholangiocarcinoma 20Keratosis, Actinic 17Carcinoma, Squamous Cell 16Biliary Tract Neoplasms 16Liver Neoplasms 15Gastrointestinal Neoplasms 15Anus Neoplasms 14Gallbladder Neoplasms 11Bile Duct Neoplasms 11Peritoneal Neoplasms 10Laryngeal Neoplasms 9Recurrence 8Nasopharyngeal Neoplasms 7Colorectal Cancer Metastatic 7

Interventions

dehydroftorafur 2Taxes 2Radiotherapy 2Radiation 2Oxaliplatin 2Leucovorin 2Irinotecan 2Fluorouracil 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2Platinum 1Nivolumab 1Gemcitabine 1Cisplatin 1Capecitabine 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Borderline Resectable Pancreatic Adenocarcinoma × Fluorouracil × Clear all
NCT04481204 2026-05-04

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

NCT03970252 2024-08-09

Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

Jonsson Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
28 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡